Trials / Completed
CompletedNCT01987947
A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of additional quilizumab therapy in adult patients with Chronic Spontaneous Urticaria resistant to antihistamine treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Two administrations by subcutaneous injection |
| DRUG | Quilizumab | Two administrations by subcutaneous injection |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2013-11-20
- Last updated
- 2016-11-02
Locations
3 sites across 2 countries: Canada, Germany
Source: ClinicalTrials.gov record NCT01987947. Inclusion in this directory is not an endorsement.